UBS Group AG DRUG — BRIGHT MINDS BIOSCIENCES INC

Ownership history in UBS Group AG  ·  8 quarters on record

AI Ownership Summary

UBS Group AG reported BRIGHT MINDS BIOSCIENCES INC (DRUG) in 8 quarterly 13F filings from 2023 Q4 through 2026 Q1. The latest visible filing shows DRUG at 0.00% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this DRUG ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was UBS Group AG's position in BRIGHT MINDS BIOSCIENCES INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q1

DRUG was reported at 0.00% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.0% in 2025 Q4

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2023 Q4 to 2026 Q1

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

DRUG stock page UBS Group AG fund profile UBS Group AG full holdings
How UBS Group AG held DRUG — position size vs. price
% of Fund (quarterly)    DRUG price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 8 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q1 REDUCED — — — 13,280 -533 -3.9% 0.00% $969K 2026-05-05 $86.22
2025 Q4 ADDED — — — 13,813 +12,224 +769.3% 0.00% $1.1M 2026-01-29 $82.48
2025 Q3 REDUCED 17.0% +28.8% ❌ 1,589 -325 -17.0% 0.00% $96K 2025-11-13 $58.36
2025 Q2 REDUCED 83.4% +120.0% ❌ 1,914 -9,621 -83.4% 0.00% $50K 2025-08-14 $42.54
2025 Q1 ADDED — — — 11,535 +1,374 +13.5% 0.00% $416K 2025-05-13 $32.61
2024 Q4 ADDED — — — 10,161 +6,754 +198.2% 0.00% $366K 2025-02-14 $41.80
2024 Q3 ADDED — — — 3,407 +2,785 +447.7% 0.00% $4K 2024-11-14 $42.95
2023 Q4 INITIATED — — — 622 — — 0.00% $889 2024-02-09 $1.91

🏢 Other funds also holding DRUG

As of 2026 Q1 — sorted by position size

AdvisorShares Investments LLC 3Y 0.17% China Universal Asset Management Co., Ltd. 3Y 0.0% Police & Firemen's Retirement System of New Jersey 0.0% STRS OHIO 3Y 7Y 0.0% Bank of New York Mellon Corp 3Y 7Y 0.0% Nuveen, LLC 0.0% GAMMA Investing LLC 0.0% Bell Investment Advisors, Inc 3Y 0.0% Sterling Capital Management LLC 3Y 7Y 0.0% SBI Securities Co., Ltd. 0.0%

FAQ About UBS Group AG and DRUG

These are the practical questions this page is built to answer before you even open the full history table.

How long has UBS Group AG reported owning DRUG?

UBS Group AG reported DRUG across 8 quarterly 13F filings, from 2023 Q4 through 2026 Q1.

What was the largest reported DRUG position in UBS Group AG's portfolio?

The largest reported portfolio weight for DRUG was 0.00% in 2025 Q4.

What is the latest reported DRUG position on this page?

The most recent filing on this page is 2026 Q1, when UBS Group AG reported 13,280 shares, equal to 0.00% of portfolio, with an estimated market value of $969K.

What does the chart on this DRUG ownership page compare?

The chart compares UBS Group AG's quarterly DRUG portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did UBS Group AG time their DRUG position?

Based on 13F filing dates vs. subsequent DRUG price moves, UBS Group AG correctly timed 3 out of 7 reported position changes (43%). The annualised alpha on DRUG relative to SPY over the holding period was +39.1%.

← Back to UBS Group AG Holdings